NEWS & PUBLICATIONS

Innovative RNA Origami Anticoagulant Research Highlighted at MSE100 Centennial Celebration

On Friday, April 5th, Thom LaBean showcased a poster titled "Multivalent, Aptamer-Decorated RNA Origami as Direct Thrombin Inhibitor with...

Helixomer Inc. Secures $2 Million NIH Award for Development of Innovative Intravenous Anticoagulant and Reversal Agent

Raleigh, NC – October, 2023 – Helixomer Inc., a pioneering entity in the realm of drug development, is pleased to announce the receipt of...

David Harrell Appointed as New President and CEO of Helixomer

Helixomer, Inc. announces the appointment of David Harrell as President and CEO, where he will lead the company's growth efforts,...

WE RECENTLY PUBLISHED A PEER-REVIEWED RESEARCH ARTICLE ON OUR RNA ANTICOAGULANT TECHNOLOGY

In the prestigious scientific journal, Advanced Materials (Impact Factor=27.4) Nucleic acid aptamers selected for thrombin binding have...

WE HAVE RECEIVED A CHANCELLOR’S INNOVATION FUND (CIF) AWARD

The funding has allowed us to pursue pre-clinical evaluation of our anticoagulant and reversal agent. "As a land-grant university, our...

A DRAFT OF OUR NEXT PAPER HAS BEEN POSTED TO BIORXIV.

The paper has also been submitted for peer-reviewed publication. Anticoagulants are commonly utilized during surgeries and to treat...